1. Home
  2. CYTK vs HL Comparison

CYTK vs HL Comparison

Compare CYTK & HL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • HL
  • Stock Information
  • Founded
  • CYTK 1997
  • HL 1891
  • Country
  • CYTK United States
  • HL United States
  • Employees
  • CYTK N/A
  • HL N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • HL Precious Metals
  • Sector
  • CYTK Health Care
  • HL Basic Materials
  • Exchange
  • CYTK Nasdaq
  • HL Nasdaq
  • Market Cap
  • CYTK 4.6B
  • HL 3.9B
  • IPO Year
  • CYTK 2004
  • HL N/A
  • Fundamental
  • Price
  • CYTK $35.39
  • HL $8.52
  • Analyst Decision
  • CYTK Buy
  • HL Hold
  • Analyst Count
  • CYTK 13
  • HL 5
  • Target Price
  • CYTK $71.58
  • HL $7.60
  • AVG Volume (30 Days)
  • CYTK 1.7M
  • HL 22.1M
  • Earning Date
  • CYTK 08-07-2025
  • HL 08-06-2025
  • Dividend Yield
  • CYTK N/A
  • HL 0.18%
  • EPS Growth
  • CYTK N/A
  • HL N/A
  • EPS
  • CYTK N/A
  • HL 0.16
  • Revenue
  • CYTK $85,738,000.00
  • HL $1,060,106,000.00
  • Revenue This Year
  • CYTK $330.96
  • HL $12.80
  • Revenue Next Year
  • CYTK $73.41
  • HL $2.00
  • P/E Ratio
  • CYTK N/A
  • HL $53.74
  • Revenue Growth
  • CYTK 2635.74
  • HL 36.30
  • 52 Week Low
  • CYTK $29.31
  • HL $4.46
  • 52 Week High
  • CYTK $59.39
  • HL $8.54
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 49.60
  • HL 78.15
  • Support Level
  • CYTK $36.89
  • HL $7.78
  • Resistance Level
  • CYTK $39.92
  • HL $8.04
  • Average True Range (ATR)
  • CYTK 1.78
  • HL 0.26
  • MACD
  • CYTK -0.06
  • HL 0.04
  • Stochastic Oscillator
  • CYTK 54.96
  • HL 97.81

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About HL Hecla Mining Company

Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.

Share on Social Networks: